Zenicor (ZENI) Investor Update summary

Business Overview and Strategic Focus

• Specializes in cardiology, focusing on arrhythmia diagnostics with medical-grade systems and services for professional healthcare, aiming to be a world leader in this field and prevent strokes from undiagnosed atrial fibrillation.

• Over 300 hospitals and clinics in Northern Europe use the solutions, with direct sales in Sweden, Finland, Norway, and the UK.

• Business model offers both pay-per-assessment and license-based revenue streams, adaptable to local reimbursement systems.

• Focus on early diagnosis to reduce healthcare costs and improve patient outcomes.

• Mission is to ensure no one suffers a stroke due to undiagnosed atrial fibrillation.

Product and Service Offerings

• Solutions include Zenicor One (handheld ECG), Zenicor Flex (continuous ECG), Zenicor View (web-based system), and Zenicor Direct (logistics and interpretation services).

• Solutions support both intermittent and continuous ECG monitoring, with AI-assisted arrhythmia detection.

• Web-based platform enables centralized management of equipment and interpretation services.

• Service packages include logistics and EKG analysis for professional healthcare.

Clinical Impact and Scientific Validation

• Products are certified for professional healthcare and supported by over 50 clinical studies showing high diagnostic yield, stroke prevention impact, and cost-effectiveness.

• Screening programs, such as Stroke Stop and SAFER, demonstrate increased detection of atrial fibrillation and potential healthcare savings.

• Ongoing large-scale studies in the UK (SAFER) and Australia aim to further validate the benefits of arrhythmia screening.

• Health economic analyses indicate substantial cost savings and improved patient quality of life.